BiomanufacturingElectrochaea sells biomethane reactor to A...Archaeal Power-to-biomethan producer Electrochaea GmbH has sold a BioCat bioreactor to the Danish CCU specialist Again A/S. more ➔
financingFlindr Therapeutics BV secures €20m Seri...Oss-based oncology company Flindr Therapeutics BV has secured €20m to advance it first-in-class RNF31 inhibitors, which destabilises E3 ubiquitin ligase. more ➔
bioeconomyNordic Bioproducts Group opens its first p...Finnish Nordic Bioproducts Group has opened a production facility to produce advanced cellulosic materials wit the start-up’s AaltoCell technology more ➔
Swiss Biotech DaySwiss Biotech Report reporting record turn...The Swiss biotech sector proved robust growth in 2023. Revenues in 2023 increased by CHF500m to CHF7.3bn. Capital investment grew to CHF2bn – just betweeen 2021 (CHF3.4bn) and 2022 (CHF1.3bn). more ➔
Drug DiscoveryIpsen puts US$1.8bn in pipeline expansion...Ipsen SA and RNA splicing modifier specialist Skyhawk Therapeutics Inc have entered a US$1.8bn licencing option deal in rare neurological disorders. more ➔
AMDSeabelife SAS to develop next-gen dry AMD...French drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy. more ➔
financingAmphiStar BV secures €6m to expand produ...Waste based biosurfactants producer Amphistar BV has closed a €6m funding round led by the European Circular Bioeconomy Fund (ECBF), Qbic III and Flanders Future Tech Fund (FFTF). more ➔
HIVNaobios and Sumagen partner to develop HIV...Vaccine maker Sumagen Co. Ltd has launched a cGMP manufacturing partnership with French Naobios SAS for clinical testing of Sumagen’s inactivated HIV vaccine candidate. more ➔
Industrial BiotechSolar Foods starts Factory01Finnish Solar Foods Oy has started microbial production of its protein powder Solein in Factory 01, Solar Foods’ first commercial-scale production facility in Vantaa, Finland. more ➔
ApprovalShock: Adrenomed AG gets FDA fast track de...German AdrenoMed AG has got FDA Fast Track designation for its targeted septic shock medicine enibarcimab that restores endothel integrity. more ➔
